A channel for precision diagnosis and treatment in genetic epilepsy

Annals of Neurology

Volumn 76, Issue 3, 2014, Pages 323-324

  Poduri, Annapurna ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEMIZOLE; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNT1; QUINIDINE; RETIGABINE; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT; KCNT1 PROTEIN, HUMAN; NERVE PROTEIN;

DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; EPILEPSY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; NOTE; POTASSIUM CURRENT; SEVERE MYOCLONIC EPILEPSY IN INFANCY; ANTAGONISTS AND INHIBITORS; EPILEPSIES, PARTIAL; FEMALE;

ANTI-ARRHYTHMIA AGENTS; EPILEPSIES, PARTIAL; FEMALE; HUMANS; NERVE TISSUE PROTEINS; POTASSIUM CHANNELS; QUINIDINE;

EID: 84907813848     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24243     Document Type: Note

References (17)

1. Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet 2012;44:1255-1259.
2. Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 2014;75:581-590.
3. Bearden D, Strong A, Ehnot J, et al. Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 2014;76:457-461.
4. Lennox WG, Lennox MA. The genetics of epilepsy. In: Epilepsy and related disorders. Vol 1. New York, NY: Little, Brown, 1960:532-574.
5. Steinlein OK, Mulley JC, Propping P, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995;11:201-203.
6. Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001;68:1327-1332.
7. Escayg A, MacDonald BT, Meisler MH, et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS12. Nat Genet 2000;24:343-345.
8. Kalachikov S, Evgrafov O, Ross B, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002;30:335-341.
9. Helbig I, Lowenstein DH. Genetics of the epilepsies: where are we and where are we going? Curr Opin Neurol 2013;26:179-185.
10. Heinzen EL, Radtke RA, Urban TJ, et al. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet 2010;86:707-718.
11. Mefford HC, Muhle H, Ostertag P, et al. Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet 2010;6:e1000962.
12. de Kovel CG, Trucks H, Helbig I, et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain 2010;133(pt 1):23-32.
13. Veeramah KR, Johnstone L, Karafet TM, et al. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia 2013;54:1270-1281.
14. Epi4K and EPGP Consortia. De novo mutation in the classic epileptic encephalopathies. Nature 2013;501:217-221.
15. Poduri A, Sheidley BR, Shostak S, Ottman R. Genetic testing in the epilepsies - developments and dilemmas. Nat Rev Neurol 2014;10:293-299.
16. Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 2013;4:2410.
17. Hu HN, Zhou PZ, Chen F, et al. Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels. Acta Pharmacol Sin 2013;34:1359-1366.